These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 21862966

  • 1. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP, Gilliland WR.
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [Abstract] [Full Text] [Related]

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [Abstract] [Full Text] [Related]

  • 4. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [Abstract] [Full Text] [Related]

  • 5. Predicting allopurinol response in patients with gout.
    Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK.
    Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
    [Abstract] [Full Text] [Related]

  • 6. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DF, Dalbeth N.
    Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
    [Abstract] [Full Text] [Related]

  • 7. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC, Salido EO, Penserga EG.
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [Abstract] [Full Text] [Related]

  • 8. Plasma oxypurinol as a measure of adherence in clinical trials.
    Stamp LK, Merriman T, Frampton C, Zhang M, Wallace M, Miner JN, Dalbeth N.
    Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
    [No Abstract] [Full Text] [Related]

  • 9. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M, Cimmino MA, Perez-Ruiz F.
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [Abstract] [Full Text] [Related]

  • 10. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L, Gow P, Sharples K, Raill B.
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [Abstract] [Full Text] [Related]

  • 11. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [Abstract] [Full Text] [Related]

  • 12. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B, Bennett K, Silke C, Whelan B.
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T, Pope JE.
    Rheumatology (Oxford); 2017 Jul 01; 56(7):1144-1153. PubMed ID: 28379501
    [Abstract] [Full Text] [Related]

  • 14. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.
    Semin Arthritis Rheum; 2015 Oct 01; 45(2):174-83. PubMed ID: 26190562
    [Abstract] [Full Text] [Related]

  • 15. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb 01; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 16. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW, Cheetham TC, Rashid N, Chang JM, Levy GD, Kerimian A, Low KJ, Redden DT, Bridges SL, Saag KG, Curtis JR, Mikuls TR.
    Contemp Clin Trials; 2016 Sep 01; 50():106-15. PubMed ID: 27449546
    [Abstract] [Full Text] [Related]

  • 17. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Koto R, Nakajima A, Horiuchi H, Yamanaka H.
    Pharmacoepidemiol Drug Saf; 2021 Feb 01; 30(2):157-168. PubMed ID: 32939919
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ.
    Ann Pharmacother; 2017 Apr 01; 51(4):301-306. PubMed ID: 27881692
    [Abstract] [Full Text] [Related]

  • 19. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C, Perez-Ruiz F.
    Eur Rev Med Pharmacol Sci; 2016 Mar 01; 20(5):983-92. PubMed ID: 27010159
    [Abstract] [Full Text] [Related]

  • 20. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.
    Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK.
    Ann Rheum Dis; 2018 Mar 01; 77(3):364-370. PubMed ID: 29146741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.